The U.S. IPO market is no longer frozen for life sciences companies; it is open, albeit selectively. A track record of strong 2026 IPOs is bringing credible issuers back to market, but investors are still demanding maturity, data and discipline. At the same time, the SEC’s pending registered offering and filer-status reforms could give newly public life sciences companies a m...
Subscribe to Public Companies & the Law’s news feed.
Click on “Follow” and decide if you want to get news from Public Companies & the Law via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to Public Companies & the Law comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from Public Companies & the Law which you are really interested in. Click on the blue “Filter” button below to get started.
Title: Public Companies & the Law